Amgen Chairman and CEO Robert Bradway touted the potential of 11 biosimilars anticipated to be driving revenues for the company by 2030.
Excitement is building at Amgen as the year 2023 draws closer and the company gets ready to launch Amjevita, its biosimilar version of adalimumab, referencing the long-reining reference product Humira, an immunosuppressive product that had $20 billion in sales in 2020.
Adalimumab is used for the treatment of multiple inflammatory conditions, including arthritis, Crohn disease, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others.
In 2021, Amgen’s biosimilar portfolio was generating annual revenues on the order of $2 billion, but with Amjevita and 6 other biosimilars in the pipeline, those revenues could “more than double” through 2030, Amgen Chairman and CEO Robert Bradway stated at the 2022 JP Morgan Healthcare Conference, held this month.
Amjevita will launch in January 2023, giving it at least a half-year head start on half-a-dozen other adalimumab biosimilars scheduled to start entering the market in June 2023. There are no adalimumab biosimilars on the market in the United States, and Amjevita will be the first, unless other contenders are able to break through innovator company AbbVie’s formidable patent barrier protecting Humira’s exclusivity. Each of the entrants scheduled so far has settled with AbbVie out of court on market timing and royalty compensation.
Bradway also described optimism for other biosimilar launches anticipated to occur shortly after Amjevita, including biosimilars for ustekinumab (Stelara), an immunosuppressive drug for plaque psoriasis and psoriatic arthritis; aflibercept (Eylea), an ophthalmology drug for age-related macular degeneration, macular edema, and diabetic retinopathy; and eculizumab (Soliris), an immunosuppressive drug used in the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Currently, Amgen has 4 oncology-centered biosimilars on the market. These include trastuzumab (Kanjinti), bevacizumab (Mvasi), infliximab (Avsola), and rituximab (Riabni). These reference Herceptin, Avastin, Remicade, and Rituxan, respectively.
Bradway said these and the anticipated launches of pipeline products, including Amjevita, which is FDA approved, would target 11 innovator or reference products in total that by themselves generate $86 billion in annual revenue.
“Clearly, we see this as an attractive franchise from the revenue standpoint,” he said.
Humira was launched in 2002, making it 20 years of exclusivity so far for AbbVie, which has raked in at least $170 billion in global revenues during that time, according to a recent congressional investigation.
Adalimumab biosimilars have been making inroads into AbbVie's Humira revenues in the European Union, where sharp declines in Humira revenues have been observed, and in Canada, recently a push by the Canadian public health authorities has put 2 new adalimumab products on the radar for health care consumers in just the past month: Yuflyma (Celltrion Healthcare) and Simlandi (Alvotech).
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.